TY - JOUR
T1 - Biological markers in transurethral biopsies from bladder cancer
T2 - Preliminary results
AU - Benini, E.
AU - Costa, A.
AU - Pizzocaro, G.
AU - Campo, B.
AU - Milani, A.
AU - Torelli, T.
AU - Veneroni, S.
AU - Ordesi, G.
AU - Pilotti, S.
AU - Silvestrini, R.
PY - 1993
Y1 - 1993
N2 - A biologic profile including proliferative activity, evaluated as
3H- thymidine labeling index (
3H-dT L1), DNA ploidy, p53 tumor-suppressor gene and P-glycoprotein (P-170), as an expression of the multidrug resistance gene, was defined for 50 primary transitional cell carcinomas of the bladder.
3H-dT LI was evaluated by autoradiography on histologic sections after incubation of fresh tumor biopsies with
3H-thymidine. Ploidy was defined by flow cytometric analysis of DNA content on nuclei suspensions obtained from frozen material. Expression of p53 protein and P-170 glycoprotein was detected by immunohistochemistry using the PAb1801 and C219 monoclonal antibody respectively, on sections from paraffin-embedded tumor biopsies. Invasive tumors showed a higher median
3H-dT L1 (12.7% vs 4.2%) and a higher frequency of aneuploidy (73% vs 43%) and more frequently expressed p53 (82% vs 36%) than superficial tumors. Further analysis showed that proliferative activity was higher in invasive than in superficial cancers only in p53- positive or aneuploid tumors and not in p53-negative or diploid tumors. Moreover, proliferative activity and p53 overexpression, but not ploidy, were directly related to histologic grading and tumor stage. Generally, P-170 was not significantly related to any biologic or clinico-pathologic factor. Kinetic and phenotypic biologic markers are differently related to clinico- pathologic factors. A panel of biologic features can be easily evaluated on small transurethral biopsies at diagnosis, during endocavitary treatment or follow-up in bladder cancer patients.
AB - A biologic profile including proliferative activity, evaluated as
3H- thymidine labeling index (
3H-dT L1), DNA ploidy, p53 tumor-suppressor gene and P-glycoprotein (P-170), as an expression of the multidrug resistance gene, was defined for 50 primary transitional cell carcinomas of the bladder.
3H-dT LI was evaluated by autoradiography on histologic sections after incubation of fresh tumor biopsies with
3H-thymidine. Ploidy was defined by flow cytometric analysis of DNA content on nuclei suspensions obtained from frozen material. Expression of p53 protein and P-170 glycoprotein was detected by immunohistochemistry using the PAb1801 and C219 monoclonal antibody respectively, on sections from paraffin-embedded tumor biopsies. Invasive tumors showed a higher median
3H-dT L1 (12.7% vs 4.2%) and a higher frequency of aneuploidy (73% vs 43%) and more frequently expressed p53 (82% vs 36%) than superficial tumors. Further analysis showed that proliferative activity was higher in invasive than in superficial cancers only in p53- positive or aneuploid tumors and not in p53-negative or diploid tumors. Moreover, proliferative activity and p53 overexpression, but not ploidy, were directly related to histologic grading and tumor stage. Generally, P-170 was not significantly related to any biologic or clinico-pathologic factor. Kinetic and phenotypic biologic markers are differently related to clinico- pathologic factors. A panel of biologic features can be easily evaluated on small transurethral biopsies at diagnosis, during endocavitary treatment or follow-up in bladder cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=0027448551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027448551&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0027448551
VL - 3
SP - 817
EP - 821
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 5
ER -